CODX Stock Pops As Co-Diagnostics Targets MENA Growth

Co-Diagnostics Inc. stocks have been trading up by 33.68 percent amid heightened optimism from its latest COVID-19 test developments.

Live Update At 10:02:35 EDT: On Thursday, May 21, 2026 Co-Diagnostics Inc. stock [NASDAQ: CODX] is trending up by 33.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CODX has turned into a wild momentum story on the chart. In late April, Co-Diagnostics was grinding around $1.50 with tight daily ranges and low excitement. That changed fast. By 2026/05/08, CODX pushed from an open near $2.16 to close around $2.53, then ripped again in mid-May, topping out near $2.75 before the real fireworks.

The last three sessions show what aggressive trading looks like. CODX bounced from a $1.37 close on 2026/05/18 to $1.97, then to $2.39, and most recently to $3.19, with intraday spikes as high as $3.45. That’s more than a double in just a few days, driven by traders crowding into the expansion and Ebola headlines.

More Breaking News

• HIVE Stock Grinds Higher As Traders Eye Breakout
• RIVN Stock Eyes R2 Launch As Volkswagen Backs Capital Push
• American Airlines Stock Climbs As Q2 Outlook, Spirit Exit Shift The Map
• QUBT Stock Jumps As Earnings Beat Fuels Quantum Hype

Fundamentals, however, paint a very different picture. Co-Diagnostics posted quarterly revenue of only about $146,000 against a net loss of roughly $9.1M and negative EBITDA near $8.9M. Profit margins are deeply negative, and revenue has dropped sharply over the last three to five years. On the positive side, CODX carries minimal debt, over $8.2M in cash, and a strong current ratio around 3.9, giving the company runway to keep funding R&D and the new Saudi push. For traders, this is a classic story: weak earnings, strong balance sheet, and heavy speculation around future catalysts.

Why Traders Are Watching CODX Right Now

CODX is back on day-trader screens because the story just got bigger than a typical micro-cap biotech grind. Co-Diagnostics and its joint venture CoMira Diagnostics have moved from talking about global expansion to actually signing for bricks and mortar. The 14,400-square-foot turnkey facility in Sudair Industrial City, Saudi Arabia, is not a press release dream. It’s a concrete step toward localized manufacturing for the Co-Dx PCR platform, lab equipment, and consumables.

For active traders, that matters. A signed lease in Saudi Arabia under the Vision 2030 umbrella signals that CODX wants to be a real player in the MENA diagnostics space, not just ship kits from afar. Local production can shorten supply chains, cut costs, and make it easier to win regional contracts once regulatory and operational approvals clear. None of that shows up as revenue today, but it builds a narrative that momentum traders can latch onto.

At the same time, Co-Diagnostics has finished an assay development strategy for the Bundibugyo strain of Ebola, following a WHO public health emergency in the DRC and Uganda. That tells traders CODX is still quick on the draw with emerging pathogens. There is no guaranteed payday from this Ebola work, yet the ability to rapidly commercialize a PCR-based Bundibugyo test if demand spikes is exactly the kind of “optionality” story that fuels speculative runs. Combined, the Saudi facility and Ebola assay give CODX two clear catalysts that explain why volume and volatility have exploded.

Conclusion

CODX is the kind of stock traders love to study: ugly income statement, strong cash cushion, and fresh global catalysts that the market can get excited about. Co-Diagnostics is still losing serious money, with more than $9M in quarterly net losses on a small revenue base, and returns on equity and assets buried deep in the red. But those losses are driven by heavy R&D and operating spend, not by a broken balance sheet. With over $8M in cash and low debt, CODX has room to keep building.

The Saudi Arabia facility via CoMira Diagnostics moves CODX from planning to execution on MENA expansion, while the Ebola Bundibugyo assay strategy reinforces its infectious disease focus. Neither catalyst guarantees future revenue, yet both give traders a clear story to track on the chart and in news feeds.

For active traders, the lesson around Co-Diagnostics is timeless. Big headlines plus tight floats can create explosive moves, but they can unwind just as fast. As Tim Sykes likes to hammer home, “trade the ticker, not the story — patterns and risk management matter more than hype.” As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. CODX offers a live case study in exactly that approach.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.